We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Biotech Companies Fight Aging at the Cellular Level

By Biotechdaily staff writers
Posted on 16 Apr 2007
Exclusively licensed from the Geron Corp. More...
(Menlo Park, CA, USA), a new product, TA-65, is the world's first telomerase activator.

Telomerase Activation Sciences, Inc. (TA Sciences; New York, NY, USA) announced its license with Geron to develop and market non-therapeutic products using Geron's small molecule telomerase activators. TA Sciences has recently opened the TA Sciences Center in New York City, where customers can purchase TA Sciences' first product, a nutraceutical containing the telomerase-activating agent TA-65.

"TA Sciences welcomes our first customers and the launch of the world's first telemetries-activator product,” said Noel Thomas Patton, founder of TA Sciences. "A natural consequence of aging is the shortening of telomeres [caps of DNA located at the ends of all chromosomes], which ultimately results in loss of cell function. TA-65 offers the potential of reducing or reversing telomere shortening and battles tissue and organ degeneration by rejuvenating aging cells.”

TA-65 is the result of vigorous scientific research that began at Geron in 1992. The response from the scientific community to the news of TA Sciences' launch has been very enthusiastic. "Telomerase Activation is the single most promising approach to reversing the effects of aging,” said Michael Fossel, M.D., Ph.D., clinical professor of medicine at Michigan State University (East Lansing, MI, USA), and specialist on aging and age- related clinical disease.

Moreover, Dr. William H. Andrews, founder of Sierra Sciences, LLC (Reno, NV, USA), and one of the principal discoverers of the telomerase genes, commented, "Cleopatra, Ponce de Leon, and untold others throughout the ages have searched for the secrets of youth. That search has been futile, until now: Telomerase Activation is the first and only scientifically sound way to approach anti-aging. TA-65 is the first product in history that has been proven to slow or reverse cellular aging.”

On April 30, 2007, TA Sciences plans to publish the results of the pivotal 2005 Anti-Aging trial, which is the first ever human-clinical trial of a telomerase activator. This trial shows statistical verification of the anti-aging benefits of telomerase activation.


Related Links:
Geron
Telomerase Activation Sciences

New
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
New
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.